Clinical trial
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic…
NCT00048139 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00048139 |
|---|---|
| Title | A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer |
| Official title | An Open-label Study of the Effect of Intermittent Xeloda in Combination With Irinotecan on Treatment Response in Patients With Advanced and/or Metastatic Colorectal Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Irinotecan, capecitabine [Xeloda] |
| Enrollment | 52 |
| Start date | Oct 1, 2001 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Oct 25, 2002 |
| Last update posted | Nov 2, 2016 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: